Table 28: Clinical evidence profile: Antidepressants (fluoxetine) versus antipsychotics (amisulpride)

Quality assessment							No of patients		Effect			
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Antidepressants (fluoxetine) versus antipsychotics (amisulpride)	Control	Relative (95% CI)	Absolute	Quality	Importance
Quality of Life: SF12 (follow-up 12 weeks; range of scores: 0-100; Better indicated by higher values)												
		, ,	no serious inconsistency		no serious imprecision	none	20	20	-	MD 15.6 lower (18.61 to 12.59 lower)	⊕OOO VERY LOW	CRITICAL
Fatigue: Fatigue Severity Scale (follow-up 12 weeks: range of scores: 9-63: Better indicated by lower values)												

	very serious¹	no serious inconsistency	serious <sup>2</sup>	no serious imprecision	none	20	20	-	MD 12.6 higher (8.26 to 16.94 higher)	⊕OOO VERY LOW	CRITICAL	
Psychological status: HADS anxiety (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)												
randomised trials		no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	20	20	-	MD 0.4 higher (0.22 lower to 1.02 higher)	⊕OOO VERY LOW	CRITICAL	
Psychological status: HADS depression (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)												
	very serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	serious³	none	20	20	-	MD 0.1 lower (0.69 lower to 0.49 higher)	⊕OOO VERY LOW	CRITICAL	
Pain: pain on VAS (follow-up 12 weeks; range of scores: 0-100; Better indicated by lower values)												
randomised trials	very serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	no serious imprecision	none	20	20	-	MD 12.6 higher (5.8 to 19.4 higher)	⊕OOO VERY LOW	CRITICAL	
Adverse events: FIBSER global burden (follow-up 12 weeks; range of scores: not reported; Better indicated by lower values)												
	very serious <sup>1</sup>	no serious inconsistency	serious <sup>2</sup>	serious <sup>3</sup>	none	20	20	-	MD 0.2 lower (0.67 lower to 0.27 higher)	⊕OOO VERY LOW	CRITICAL	
Symptom scales: Clinical Global Impression Severity (CGI-S) (follow-up 12 weeks; range of scores: 1-7; Better indicated by lower values)												
trials	serious <sup>1</sup>	inconsistency	serious <sup>2</sup>	no serious imprecision	none	20	20	-	MD 1.3 higher (0.75 to 1.85 higher)	⊕OOO VERY LOW	CRITICAL	
	randomised trials  randomised trials  randomised trials  randomised trials  randomised trials  randomised trials  events: FIBS  randomised trials  randomised trials	trials serious¹  pgical status: HADS an randomised trials very serious¹  pgical status: HADS de randomised trials very serious¹  n on VAS (follow-up 12 randomised trials very serious¹  events: FIBSER global randomised trials very serious¹  n scales: Clinical Global randomised trials very serious¹	trials serious¹ inconsistency  pgical status: HADS anxiety (follow-up 1 randomised trials very serious¹ no serious inconsistency  pgical status: HADS depression (follow-up 1) randomised trials very serious¹ no serious inconsistency  no no VAS (follow-up 12 weeks; range of randomised trials very serious¹ no serious inconsistency  events: FIBSER global burden (follow-up 1) randomised trials very serious¹ no serious inconsistency  no serious no serious inconsistency  no serious inconsistency  no serious inconsistency  no serious inconsistency	trials serious¹ inconsistency  pgical status: HADS anxiety (follow-up 12 weeks; range of serious²  pgical status: HADS depression (follow-up 12 weeks; range of serious²  pgical status: HADS depression (follow-up 12 weeks; range of serious²  prandomised trials very serious¹ no serious serious²  prandomised trials very serious¹ no serious serious²	trials seríous¹ inconsistency imprecision  pgical status: HADS anxiety (follow-up 12 weeks; range of scores: 0-  randomised trials very serious¹ no serious inconsistency serious² serious³  pgical status: HADS depression (follow-up 12 weeks; range of scores: 0-  randomised trials very serious¹ no serious inconsistency serious² serious³  no no VAS (follow-up 12 weeks; range of scores: 0-100; Better indicated serious¹ no serious inconsistency serious² no serious inconsistency serious² serious² no serious inconsistency serious² serious² no serious inconsistency serious² no serious inconsistency serious² no serious inconsistency serious² no serious inconsistency	trials serious¹ inconsistency imprecision  pgical status: HADS anxiety (follow-up 12 weeks; range of scores: 0-21; Better indicate randomised trials very serious¹ no serious inconsistency serious² serious³ none  pgical status: HADS depression (follow-up 12 weeks; range of scores: 0-21; Better indicated randomised trials very serious¹ no serious serious² serious³ none  n on VAS (follow-up 12 weeks; range of scores: 0-100; Better indicated by lower value randomised very serious¹ no serious serious² no serious inconsistency inconsistency serious² serious² no serious inconsistency serious² serious² no serious inconsistency serious² serious² none inconsistency serious² serious² none serious serious² serious² none serious inconsistency serious² serious³ none inconsistency serious² serious² none serious inconsistency serious² serious² none inconsistency serious² none inconsistency serious² none inconsistency serious² no serious inconsistency serious² no serious inconsistency serious² no serious inconsistency serious² no serious inconsistency i	trials seríous¹ inconsistency imprecision  gical status: HADS anxiety (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)  randomised very serious¹ no serious serious² serious³ none 20  gical status: HADS depression (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)  randomised very serious¹ no serious serious² serious³ none 20  non VAS (follow-up 12 weeks; range of scores: 0-10; Better indicated by lower values)  randomised very serious¹ no serious serious² no serious inconsistency inconsistency serious² no serious mprecision  events: FIBSER global burden (follow-up 12 weeks; range of scores: not reported; Better indicated by lower values)  randomised very serious¹ no serious serious² serious² none 20  events: FIBSER global burden (follow-up 12 weeks; range of scores: not reported; Better indicated by lower values)  randomised very serious¹ no serious serious² serious² none 20  n scales: Clinical Global Impression Severity (CGI-S) (follow-up 12 weeks; range of scores: 1-7; Better indicated by lower values)  randomised very serious¹ no serious inconsistency serious² no serious inconsistency inconsistency serious² none 20	trials serious¹ inconsistency imprecision  gical status: HADS anxiety (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)  randomised very trials very inconsistency serious² serious³ none 20 20  gical status: HADS depression (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)  randomised trials very inconsistency serious² serious³ none 20 20  non VAS (follow-up 12 weeks; range of scores: 0-100; Better indicated by lower values)  randomised trials very inconsistency serious serious² serious none 20 20  randomised trials very inconsistency serious serious² serious none 20 20  events: FIBSER global burden (follow-up 12 weeks; range of scores: not reported; Better indicated by lower values)  randomised trials very inconsistency serious² serious² none 20 20  events: FIBSER global burden (follow-up 12 weeks; range of scores: not reported; Better indicated by lower values)  randomised trials very inconsistency serious² serious² none 20 20  serious none 20 20  a scales: Clinical Global Impression Severity (CGI-S) (follow-up 12 weeks; range of scores: 1-7; Better indicated by lower values)  randomised very serious¹ no serious serious² none 20 20  a scales: Clinical Global Impression Severity (CGI-S) (follow-up 12 weeks; range of scores: 1-7; Better indicated by lower values)  randomised very serious¹ no serious inconsistency serious² no serious imprecision none 20 20	trials serious¹ inconsistency imprecision  gical status: HADS anxiety (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)  randomised very serious¹ inconsistency serious² serious² none 20 20 -  gical status: HADS depression (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)  randomised very serious¹ inconsistency serious² serious² none 20 20 -  n on VAS (follow-up 12 weeks; range of scores: 0-100; Better indicated by lower values)  randomised very serious¹ inconsistency serious² no serious inprecision none 20 20 -  events: FIBSER global burden (follow-up 12 weeks; range of scores: not reported; Better indicated by lower values)  randomised very serious¹ inconsistency serious² serious² none 20 20 -  events: FIBSER global burden (follow-up 12 weeks; range of scores: not reported; Better indicated by lower values)  randomised very serious¹ inconsistency serious² serious² none 20 20 -  n scales: Clinical Global Impression Severity (CGI-S) (follow-up 12 weeks; range of scores: 1-7; Better indicated by lower values)  randomised very serious¹ no serious serious² none 20 20 -  n scales: Clinical Global Impression Severity (CGI-S) (follow-up 12 weeks; range of scores: 1-7; Better indicated by lower values)  randomised very serious¹ no serious inconsistency inconsisten	trials serious¹ inconsistency imprecision (8.26 to 16.94 higher)  randomised trials very no serious inconsistency serious² serious³ none 20 20 - MD 0.1 lower (0.22 lower to 1.02 higher)  randomised very serious¹ no serious serious² serious³ none 20 20 - MD 0.1 lower (0.28 lower to 1.02 higher)  randomised very serious¹ no serious serious² serious³ none 20 20 - MD 0.1 lower (0.69 higher)  randomised very serious¹ no serious serious² serious² serious³ none 20 20 - MD 0.1 lower (0.69 higher)  randomised very inconsistency serious² no serious serious¹ none 20 20 - MD 0.1 lower (0.69 higher)  randomised very inconsistency serious² no serious serious² none 20 20 - MD 0.1 lower (0.69 higher)  randomised very inconsistency serious² no serious serious² no serious imprecision none 20 20 - MD 1.2.6 higher (5.8 to 19.4 higher)  randomised very serious¹ no serious serious² serious² none 20 20 - MD 0.2 lower (0.67 tower to 0.27 higher)  randomised very serious¹ no serious serious² serious² serious³ none 20 20 - MD 0.2 lower (0.67 lower to 0.27 higher)  randomised very no serious serious² serious² serious³ none 20 20 - MD 0.2 lower (0.67 lower to 0.27 higher)  randomised very no serious serious² serious² none 20 20 - MD 0.1 higher)  randomised very no serious serious² serious² none 20 20 - MD 0.1 higher)  randomised very no serious serious² serious² none 20 20 - MD 1.3 higher (0.75 to 1.85 higher)	trials serious¹ inconsistency imprecision (8.26 to 16.94 higher) VERY LOW copical status: HADS anxiety (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)  randomised very inconsistency inconsistency serious² serious² serious³ none 20 20 - MD 0.4 higher (0.22 lower to 1.02 VERY higher) LOW copical status: HADS depression (follow-up 12 weeks; range of scores: 0-21; Better indicated by lower values)  randomised very inconsistency no serious serious² serious³ none 20 20 - MD 0.1 lower (0.69 6000 VERY LOW very higher) LOW very higher)  randomised very serious¹ no serious serious² serious² no none 20 20 - MD 0.1 lower (0.69 6000 VERY LOW very higher) lower to 0.49 higher)  randomised very serious¹ no serious serious² serious² no serious imprecision none 20 20 - MD 12.6 higher (5.8 to 19.4 higher) LOW very liniconsistency very serious¹ inconsistency no serious serious² no serious imprecision none 20 20 - MD 12.6 higher (5.8 to 19.4 higher) VERY LOW very liniconsistency very liniconsistency no serious serious¹ none 20 20 - MD 12.6 higher (5.8 to 19.4 higher) VERY LOW very liniconsistency very liniconsistency no serious serious² serious² none 20 20 - MD 0.2 lower (0.67 lower to 0.27 VERY LOW very liniconsistency liniconsistency no serious serious² none 20 20 - MD 0.2 lower (0.67 lower to 0.27 VERY LOW very liniconsistency liniconsistency liniconsistency liniconsistency no serious liniconsistency liniconsistency liniconsistency no serious liniconsistency linico	

Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

The majority of the evidence included an indirect population (downgraded by one increment) or a very indirect population (downgraded by two increments). Populations were downgraded if the ME/CFS diagnostic criteria used did not include PEM as a compulsory feature

Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs